Inhibitor Therapeutics, Inc. INTI
0.08 USD 0.00 (+0.00%)
Regular-session close
0.0799 Day range 0.08
0.04 52-week range 0.124
- YTD
- +77.78%
- 1 year
- +60.00%
News
globenewswire.com Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly…
globenewswire.com Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical…
globenewswire.com Complement Inhibitor Therapeutics Pipeline Developments Research Report 2024 Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Complement Inhibitors - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
globenewswire.com Complement Inhibitors Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of Complement Inhibitor Therapeutics | DelveInsight The complement inhibitors market is gaining momentum due to the rising recognition of the complement system's role in driving rare and chronic diseases, such as paroxysmal nocturnal hemoglobinuria…
globenewswire.com Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan TAMPA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) today provided an update on development efforts for its itraconazole formulation for the…
zacks.com 3 Intriguing Stocks to Watch as Earnings Approach As beneficiaries of strong business industries, Intuit (INTU), Workday (WDAY), and Booz Allen Hamilton's (BAH) stock all sport a Zacks Rank #2 (Buy) ahead of their quarterly reports this week.
prnewswire.com Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board Scientific Advisory Board tasked with critical review of Phase 2b trial results to assess clinical usefulness prior to submission of New Drug Application ("NDA") to FDA TAMPA, Fla. , Dec. 19, 2023…
